Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

The MONARK study was a pilot randomized trial comparing the safety and efficacy of lopinavir-ritonavir (LPV/r) monotherapy to those of LPV/r-zidovudine-lamivudine triple therapy for antiretroviral-naïve human immunodeficiency virus type 1 (HIV-1)-infected patients. Resistance testing was performed a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Delaugerre, Constance, Flandre, Philippe, Chaix, Marie Laure, Ghosn, Jade, Raffi, François, Dellamonica, Pierre, Jaeger, H., Shürmann, D., Cohen-Codar, Isabelle, Ngo Van, Philippe, Norton, Michael, Taburet, Anne-Marie, Delfraissy, Jean-François, Rouzioux, Christine
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology (ASM) 2009
Soggetti:
Antiviral Agents
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2704639/
https://ncbi.nlm.nih.gov/pubmed/19451297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01643-08
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi